Tier 2 — strong

Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial

Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM
Nutrients 2021 14(1):124

Bibliography

PubMed
PMID 35010998
PubMed Central
PMC8746601
Funding
Funded by NNB Nutrition.
Competing interests
One author was a paid adviser to NNB Nutrition; a conflict-management arrangement was reported.

Study snapshot

DesignDouble-blind randomized crossover pilot
ModelHuman participants; see population
Sample5 healthy men
InterventionFour-dose conditions: berberine 500 mg, dihydroberberine 100 or 200 mg, or placebo
DurationAcute crossover with 2-hour sampling after the fourth dose
EndpointsPlasma exposure and pharmacokinetics; Drug interaction measurements; Short-term tolerability

What the study showed, in plain terms

Dihydroberberine produced higher measured berberine exposure than standard berberine. Glucose and insulin responses did not significantly differ.

Key findings

  • Dihydroberberine produced higher measured berberine exposure than standard berberine. Glucose and insulin responses did not significantly differ.

What this study can and cannot tell us

Five participants and short sampling. Higher exposure is not demonstrated superior glucose control or long-term safety.

Citation network

Articles citing this research paper

12 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified